AMRX Amneal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSE: AMRX

Price (delayed)

$7.43

Market cap

$2.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.74

Enterprise value

$4.99B

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in ...

Highlights
The company's gross profit rose by 12% YoY and by 7% QoQ
AMRX's revenue is up by 10% year-on-year and by 4.2% since the previous quarter
AMRX's EPS has dropped by 54% since the previous quarter but it is up by 18% year-on-year
AMRX's quick ratio is down by 12% YoY but it is up by 3.6% from the previous quarter
Amneal Pharmaceuticals's equity has shrunk by 122% YoY
The company's net income has shrunk by 101% QoQ and by 25% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amneal.com
Peers: NWBO

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
308.65M
Market cap
$2.29B
Enterprise value
$4.99B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.91
EV/EBIT
69.02
EV/EBITDA
16.68
EV/Sales
2
Earnings
Revenue
$2.5B
EBIT
$72.26M
EBITDA
$299.04M
Free cash flow
$155.99M
Per share
EPS
-$0.74
Free cash flow per share
$0.51
Book value per share
-$0.21
Revenue per share
$8.12
TBVPS
$6.5
Balance sheet
Total assets
$3.46B
Total liabilities
$3.52B
Debt
$2.75B
Equity
-$63.72M
Working capital
$545.66M
Liquidity
Debt to equity
-43.09
Current ratio
1.65
Quick ratio
0.87
Net debt/EBITDA
9.01
Margins
EBITDA margin
12%
Gross margin
35.3%
Net margin
-6.8%
Operating margin
5.7%
Efficiency
Return on assets
-4.7%
Return on equity
-111.5%
Return on invested capital
1.8%
Return on capital employed
2.8%
Return on sales
2.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
0.68%
1 week
2.62%
1 month
14.84%
1 year
143.61%
YTD
22.41%
QTD
17.01%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.5B
Gross profit
$880.44M
Operating income
$142.33M
Net income
-$168.69M
Gross margin
35.3%
Net margin
-6.8%
The company's net income has shrunk by 101% QoQ and by 25% YoY
AMRX's net margin has dropped by 94% since the previous quarter and by 15% year-on-year
The operating margin has declined by 28% since the previous quarter
The company's operating income fell by 25% QoQ

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
AMRX P/E details
P/E
N/A
P/B
N/A
P/S
0.91
EV/EBIT
69.02
EV/EBITDA
16.68
EV/Sales
2
AMRX's EPS has dropped by 54% since the previous quarter but it is up by 18% year-on-year
Amneal Pharmaceuticals's equity has shrunk by 122% YoY
The price to sales (P/S) is 128% higher than the last 4 quarters average of 0.4
AMRX's revenue is up by 10% year-on-year and by 4.2% since the previous quarter

Efficiency

How efficient is Amneal Pharmaceuticals business performance
Amneal Pharmaceuticals's return on equity has shrunk by 142% YoY
The company's return on assets has shrunk by 104% QoQ and by 34% YoY
AMRX's ROIC has soared by 50% YoY but it is down by 47% from the previous quarter
AMRX's ROS is down by 48% since the previous quarter but it is up by 32% year-on-year

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's quick ratio is down by 12% YoY but it is up by 3.6% from the previous quarter
The company's current ratio fell by 11% YoY
The company's debt to equity has shrunk by 131% QoQ
Amneal Pharmaceuticals's equity has shrunk by 122% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.